Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial-Reference-Cited by-同舟云学术

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Published:2022-07 Issue: Volume:41 Page:16-23
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Izumi Kouji^ORCID,Shima Takashi,Mita Koji,Kato Yuki,Kamiyama Manabu,Inoue Shogo,Tanaka Nobumichi,Hoshi Seiji,Okamura Takehiko,Yoshio Yuko,Enokida Hideki,Chikazawa Ippei,Kawai Noriyasu,Hashimoto Kohei,Fukagai Takashi,Shigehara Kazuyoshi,Takahara Shizuko,Kadono Yoshifumi,Mizokami Atsushi

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Epidemiology and genomics of prostate cancer in Asian men;Zhu;Nat Rev Urol,2021

3. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013;Katanoda;Jpn J Clin Oncol,2015

4. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma;Samson;Cancer,2002

5. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials;Prostate Cancer Trialists’ Collaborative Group;Lancet,2000

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal;Clinical Genitourinary Cancer;2024-12

2. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

3. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa;Cancers;2024-01-24

4. Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2023-09-29

5. Adverse Events of Abiraterone Acetate vs Enzalutamide;Urology Practice;2023-07